Close

Neurocrine Biosciences (NBIX) Announces FDA Orphan Drug Designation for Valbenazine for Treatment of Pediatric Patients With Tourette Syndrome

October 23, 2017 4:58 PM EDT Send to a Friend
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that valbenazine, a novel selective vesicular monoamine transporter 2 (VMAT2), has been granted ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login